公司资料
Cel-Sci Corporation 股价、新闻与催化剂
- 股票代码:
- CVM
- 交易所:
- AMEX
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.09 USD (+1.46%)
收盘价
最后更新: 2026年10月1日
21.6M USD
市值
股价为何变动
截至 2026年10月1日，CVM 上涨 1.46%，收于 $2.09。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Neoadjuvant Cancer Immunotherapy Company
CEL-SCI develops immunotherapies intended to activate the immune system before conventional cancer treatment. Its lead program is directed at newly diagnosed head and neck cancer patients with a defined clinical and biomarker profile.
Multikine Lead Program
Multikine, also known as Leukocyte Interleukin Injection, is a mixture of immune-active proteins administered around the tumor and nearby lymph nodes. Treatment is given before surgery and radiotherapy, when the immune system is less affected by prior cancer therapy.
Head and Neck Cancer Population
The planned confirmatory program focuses on patients with advanced primary squamous cell carcinoma of the head and neck who have no lymph-node involvement and low tumor PD-L1 expression. This subgroup was identified from the company's completed Phase 3 study.
Confirmatory Registration Strategy
The FDA has allowed a confirmatory registration study designed to reproduce the survival benefit observed in the selected population. CEL-SCI must finance and execute this study before Multikine can support a regulatory submission.
LEAPS Research Platform
The company also owns the LEAPS peptide-based immunotherapy platform. Earlier research has explored LEAPS candidates in inflammatory and autoimmune diseases, including rheumatoid arthritis.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。